PHARMACOKINETICS OF MYCOPHENOLATE MOFETIL WITH VALGANCICLOVIR IN RENAL AND HEART

霉酚酸吗替酯与缬更昔洛韦在肾脏和心脏中的药代动力学

• 批准号: 7376604
• 负责人: JEONG HUN PARK
• 金额: $ 0.82万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-05 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376604
• 关键词: Herpesviridae disease; blood; decision making; dosage; heart; immune system; kidney; mycophenolate mofetil

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to evaluate the effects of valganciclovir (VGCV) on how the body handles mycophenolate mofetil (MMF) in kidney and heart transplant patients. VGCV and MMF are FDA-approved drugs given to kidney and heart transplant patients: VGCV to prevent cytomegalovirus infection and MMF to suppress their immune system to their body does not reject the transplanted organ. Active forms of MMF and VGCV are cleared through the kidney, but there is no data on how VGCV effects MMF concentrations in the body when two drugs are given together. Because both MMF and VGCV cause similar side effects, clinicians are often challenged when making decisions regarding whether the dosage of one or both rugs should be reduced. The 12-hour blood studies to measure drug concentrations will be conducted on 2 occasions: 1st study during MMF and VGCV therapy and 2nd study with MMF alone after VGCV discontinuation. The results of this study will help clinicians develop dosing guidelines if there is an interaction between MMF and VGCV.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的目的是评估缬更昔洛韦（VGCV）对肾脏和心脏移植患者的身体如何处理霉酚酸酯（MMF）的影响。VGCV和霉酚酸酯是FDA批准的药物给予肾脏和心脏移植患者：VGCV，以防止巨细胞病毒感染和霉酚酸酯，以抑制他们的免疫系统，他们的身体不排斥移植器官。活性形式的MMF和VGCV通过肾脏清除，但当两种药物一起给药时，没有关于VGCV如何影响体内MMF浓度的数据。由于MMF和VGCV引起类似的副作用，临床医生在决定是否应该减少一种或两种地毯的剂量时经常受到挑战。将在两种情况下进行12小时血液研究以测量药物浓度：第一项研究在MMF和VGCV治疗期间进行，第二项研究在VGCV停药后单独使用MMF。如果MMF和VGCV之间存在相互作用，本研究的结果将有助于临床医生制定给药指南。